Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

Dear Annie: I just read your column about the woman whose sister-in-law has become exceedingly short-tempered and abusive, ...

YORVIPATH is a first-in-class PTH replacement therapy. A prodrug of parathyroid hormone (PTH [1-34]), YORVIPATH is administered subcutaneously once daily, with sustained release of active PTH designed ...

US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

People with celiac disease often have low calcium levels, the reasons for which are complex and involve parathyroid hormone ...

Hypoparathyroidism (hypoPT) is an uncommon condition that happens when your body doesn’t make enough parathyroid hormone (PTH) or the blood levels of PTH are undetectable. How Do You Know If ...

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.